Current and emerging drugs for acute bacterial skin and skin structure infections: An update

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 431-440

  Kollipara, Ramya ^a   Downing, Christopher ^a   Lee, Michael ^a   Guidry, Jacqueline ^a   Curtis, Stephen ^a   Tyring, Stephen ^a,b  

^a CENTER FOR CLINICAL STUDIES   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute bacterial skin and skin structure infection; Antibiotic resistance; Antibiotics; CSSTIs; Methicillin resistant Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT;

ACUTE DISEASE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFECTS; FOOD AND DRUG ADMINISTRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTIDRUG RESISTANCE; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; UNITED STATES;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84906814828     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.955015     Document Type: Review

References (77)

1. Moran GJ, Abrahamian FM, Lovecchio F, et al. Acute bacterial skin. infections: developments Since the 2005 Infectious Diseases Society of America (IDSA) Guidelines. J Emerg Med 2013;44:e397-412
2. Burke SL, Rose WE. New pharmacological treatments for methicillin-resistant infections. Expert Opin Pharmacother 2014;15:1-9
3. Kujath P, Kujath C. Complicated skin, skin structure and soft tissue infections - Are we threatened by multi-resistant pathogens? Eur J Med Res 2010;15:544-53
4. Ray G, Suaya J, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U. S. population: a retrospective populationbased study. BMC Infect Dis 2013;13:252
5. Wilcox MH. Future gazing in the management of multiply drug-resistant Gram-positive infection. J Infect 2009;59(Suppl 1):S75-80
6. Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J Med Microbiol 2012;61:1179-93
7. Rodvold KA, Mcconeghy KW. Methicillin-resistant staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 2013;58(Suppl 1):S20-7
8. Stevens DL. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect 2009;59:S32-9
9. Rybak JM, Barber KE, Rybak MJ. Current and prospective treatments for multidrug-resistant Gram-positive infections. Expert Opin Pharmacother 2013;14:1919-32
10. van Hal SJ, Peterson D L. New Grampositive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011;24:515-20
11. Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistantstaphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011;86:1230-43
12. Napolitano LM. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 2008;9(Suppl 1):s17-27
13. Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillinresistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014;20:3-18
14. Liu C, Talan DA, Cosgrove SE, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Disease Society of America. Clin Infect Dis 2014;59:e10-52
15. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010;15:554-63
16. Liapikou A, Torres A. Emerging drugs on methicillin-resistant. Expert Opin Emerg Drugs 2013;18:291-305
17. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139
18. Avent ML, Vaska VL, Rogers BA, et al. Vancomycin therapeutics and monitoring: a contemporary approach. Int Med J 2013;43:110-19
19. Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clin Infect Dis 2006;42:S35-9
20. Rybak M, Lomaestro B, Rotschafer J, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-System Pharmacists, and The Society Of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7
21. Vandecasteele SJ, Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 2013;68:743-8
22. O'Brien DJ, Gould IM. Does vancomycin have a future in the treatment of skin infections? Curr Opin Infect Dis 2014;27:146-54
23. Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev Anti Infect Ther 2006;4:357-66
24. Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013;9:103-66
25. Hair P, Keam S. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007;67:1483-512
26. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65:iii35-44
27. Robbel L, Marahiel MA. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 2010;285:27501-8
28. White B, Seaton R. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 2011;4:115-27
29. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-6
30. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-72
31. Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709
32. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71
33. Tasina E, Haidich A-B, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44
34. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94
35. Saravolatz L, Stein G, Johnson L. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-14
36. Chang MH, Kish TD, Fung HB. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria in adults. Clin Ther 2010;32:2160-85
37. Polyzos KA, Mavros M, Vardakas KZ, et al. Efficacy and Safety of Telavancin in Clinical Trials: a Systematic Review and Meta-Analysis. PLoS One 2012;7:e41870
38. Goodman J, Martin S. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 2012;8:149-56
39. Casapao AM, Steed ME, Levine DP, et al. Ceftaroline fosamil for communityacquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother 2012;13:1177-86
40. Lodise TP, Low DE. Ceftaroline Fosamil in the Treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012;72:1473-93
41. Corey G, Wilcox M, Talbot G, et al. Integrated analysis of CANVAS. 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;5:641-50
42. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant staphylococcus aureus. Clin Infect Dis 2011;52:1156-63
43. Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013;73:1067-94
44. File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012;55:S173-80
45. Hernandez PO, Lema S, Tyring SK, et al. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist 2012;5:23-35
46. Chambers H. Pharmacology and the treatment of complicated skin and skinstructure infections. N Engl J Med 2014;370:2238-9
47. Zhanel G, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86
48. Boucher H, Wilcox M, Talbot G, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370:2169-79
49. FDA approves Dalvance to treat skin infections. US Food and Drug Administration. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements.htm [Last accessed 2 July 2006]
50. Prokocimer P, Bien P, Deanda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:4608-13
51. FDA approves Sivextro to treat skin infections. US Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom.htm [Last Accessed 2 July 2006]
52. Prokocimer P, Anda CD, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69
53. Moran G, Fang E, Corey G, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skinstructure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014;14(8):696-705
54. Suaya J, Mera R, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus. BMC Infect Dis 2014;14:296
55. Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008;32:149-67
56. Falconer SB, Brown ED. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009;12:497-504
57. D'Elia MA, Henderson JA, Beveridge TJ, et al. The Nacetylmannosaminetransferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 2009;191:4030-4
58. Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for Grampositive pathogens. Nature 2009;458:83-6
59. Pucci MJ, Page MGP, Bush K. Optimism for the Antibiotic Pipeline. Microbe 2014;9:147-52
60. Barczak AK, Hung DT. Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol 2009;12:490-6
61. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002;418:884-993
62. Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect 2009;22:197-203
63. Noel GJ, Draper MP, Hait H, et al. A randomized, evaluator-blind, Phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:5650-4
64. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54:S214-19
65. Karaoui LR, El-Lababidi R, Chahine EB. Oritavancin: an investigational lipoglycopeptide antibiotic. Am J Health Syst Pharm 2012;70:23-33
66. Corey G, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370:2180-90
67. Bustos C, Pozo JD. Emerging agents to combat complicated and resistant infections: focus on ceftobiprole. Infect Drug Resist 2010;3:5-14
68. Barbour A, Derendorf H. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Ther Clin Risk Manag 2010;6:485-95
69. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44
70. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprolemedocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
71. Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Med Clin North Am 2011;95:743-60
72. Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010;67:983-93
73. Krievins D, Brandt R, Hawser S, et al. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009;53:834-40
74. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
75. Nielsen SL, Black FT. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J Antimicrob Chemother 1998;42:221-6
76. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999;12(Suppl 2):S45-58
77. Craft JC, Moriarty SR, Clark K, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011;52:S520-6